摘要
目的观察玻璃体内注射Lucentis治疗糖尿病黄斑水肿的效果。方法确诊为糖尿病黄斑水肿者30例33眼,给予玻璃体内注射10 g·L-1Lucentis 0.05 mL,观察治疗前和治疗后1 d、1个月、3个月、6个月时患者的最佳矫正视力(best-corrected visual acuity,BCVA)、黄斑区中心凹厚度(central retinal thickness,CRT)和黄斑区1 mm直径平均体积(central macular volume,CMV),并分析患者治疗后3个月BCVA与性别、年龄、病程、治疗前BCVA、DME类型、CRT和CMV的变化之间的相关性。结果 33眼治疗前后眼压差异均无统计学意义(P>0.05)。治疗前BCVA、CRT、CMV分别为(15.6±10.7)个字母数、(499.3±186.1)μm、(0.332±0.132)mm3。治疗后1 d、1个月、3个月、6个月的BCVA分别是(21.7±13.7)个字母数、(25.2±14.2)个字母数、(30.7±12.9)个字母数、(30.2±14.5)个字母数,CRT分别为(407.4±176.5)μm、(303.8±94.4)μm、(231.7±43.3)μm、(244.9±66.6)μm,CMV分别为(0.278±0.161)mm3、(0.228±0.104)mm3、(0.205±0.089)mm3、(0.203±0.113)mm3。治疗后1 d、1个月、3个月、6个月的BCVA、CRT、CMV均优于治疗前(均为P<0.05)。治疗后各时间点间比较,除治疗后3个月与6个月间BCVA、CRT、CMV差异无统计学意义(均为P>0.05)外,其余各时间点间3项指标差异均有统计学意义(均为P<0.05)。治疗后3个月BCVA与病程、治疗前BCVA、CRT和CMV的变化相关(均为P<0.05),与性别、年龄、DME类型不相关(均为P>0.05)。结论玻璃体内注射Lucentis可以有效治疗糖尿病黄斑水肿,提高视力,且预后与治疗前BCVA、病程、治疗后黄斑水肿减轻程度具有相关性。
Objective To observe the clinical therapeutic efficacy of intravitreal injection of Lucentis for diabetic macular edema （DME）. Methods Thirty cases of 33 eyes diagnosed as DME were collected, the intravitreal injection of 0. 05 mL Lucentis （10 g·L^-1） was performed,and the best-corrected visual acuity （BCVA） ,central retinal thickness （CRT） and central macular volume （CMV） with lmm diameter were measured and recorded at 1 day, 1 month,3 months,5 months after injection. Then the relationship between BCVA at 3 months after injection and sexual, age, duration, BCVA before injection,type of DME, CRT, CMV were analyzed. Results There was no statistical difference in intraocular pressure before and after injection of all 33 eyes （P 〉 0. 05 ）. The BCVA,CRT and CMV before injection were 15.6 ± 10.7, （499.3 ± 185.1 ） μm and（0.332 ±0. 132）mm^3. The BCVA at 1 day,1 month,3 months and 6 months after injection were 21.7 ± 13.7,25.2 ± 14.2,30. 7 ± 12.9 and 30.2 ± 14.5 ,respectively. The CRT at those time points were （407.4 ± 175.5） μm, （303.8 ±94.4） μm, （231.7 ±43.3） μm and（244.9 ± 56.5） μm, respectively. The CMV were （0. 278 ± 0. 151 ）mm^3, （0. 228 ± 0. 104） mm^3, （0. 205 ± 0. 089 ） mm^3 and （0. 203 ± 0. 113 ） mm^3, respectively. Except for 3 months and 6 months after injection, the BCVA, CRT and CMV at other time after injection were better than before injection, and the differences were statistical significant（ all P 〈 0.05）. The BCVA at 3 months after injection were related to the disease duration, preoperative BCVA, CRT and CMV changes （ all P 〈 0.05 ）, had no relationship with sexual, age and type of DME （ all P 〉 0.05 ）. Conclusions The intravitreal injection of Lucentis is effective for treating the DME and improving the BCVA, and the postoperative BCVA recovery are dependent to the preoperative BCVA, disease duration and postoperative DME degree.
出处
《眼科新进展》
CAS
北大核心
2015年第1期45-47,共3页
Recent Advances in Ophthalmology
基金
佛山市医学类科技攻关项目(编号:201308098)~~
